Sangamo Biosciences Stock News

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob

BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES PARTICIPATION AT UPCOMING INVESTOR CONFERENCES

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob Sch

Sangamo (SGMO) delivered earnings and revenue surprises of 6.25% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sangamo (SGMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Cowen 42nd Annual Health Care Conference Date: Monday, March 7th at 12:50 p.m. Eastern Time Barclays Global Healthcare Conference Date: Thursday, March 17th at 9:00 a.m. Eastern Time H.C. Wainwright & Co. Gene Editing and Therapy Conference 2022 Date: Wednesday, March 30th at 7:00 a.m. Eastern T

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: C

Sangamo Therapeutics'' (SGMO) Q4 2021 beats on the top and bottom lines has propelled the stock 5% higher in after-hours trading.

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2021 Results - Earnings Call Transcript

Sangamo Therapeutics press release (SGMO): Q4 GAAP EPS of -$0.26 beats by $0.09.Revenue of $28M (+8.5% Y/Y) beats by $0.64M.Cash, cash equivalents and marketable securities as…

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights. “In 2021, we continued to advance the development of genomic medicines for patients across multiple therapeutic areas using our innovative technologies,” said Sandy Macrae, Chief Executive Officer of Sangamo. “We along with our partners presented compelling clinical data in our three lead pro

Sangamo (SGMO) delivered earnings and revenue surprises of 23.53% and 4.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?